Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Investigations of Alzheimer’s disease (AD), traumatic brain injury (TBI), and related brain disorders have provided extensive evidence for involvement of cathepsin B, a lysosomal cysteine protease, in mediating the behavioral deficits and neuropathology of these neurodegenerative diseases. This review integrates findings of cathepsin B regulation in clinical biomarker studies, animal model genetic and inhibitor evaluations, structural studies, and lysosomal cell biological mechanisms in AD, TBI, and related brain disorders. The results together indicate the role of cathepsin B in the behavioral deficits and neuropathology of these disorders. Lysosomal leakage occurs in AD and TBI, and related neurodegeneration, which leads to the hypothesis that cathepsin B is redistributed from the lysosome to the cytosol where it initiates cell death and inflammation processes associated with neurodegeneration. These results together implicate cathepsin B as a major contributor to these neuropathological changes and behavioral deficits. These findings support the investigation of cathepsin B as a potential drug target for therapeutic discovery and treatment of AD, TBI, and TBI-related brain disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UniProt: a worldwide hub of protein knowledge
The UniProt Consortium (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1049 · Cited by 7,698
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“Aging is a main risk factor for AD and numerous neurodegenerative diseases (33, 34).”
Backgroundde Duve, C., & Wattiaux, R. (1966) · Annual Review of Physiology · doi:10.1146/annurev.ph.28.030166.002251 · Cited by 3,033
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Tjäderhane, L., Buzalaf, M. A. R., Carrilho, M., & Chaussain, C. (2015) · Caries Research · doi:10.1159/000363582 · Cited by 2,306
Dominy, S. S., Lynch, C., Ermini, F., Benedyk, M., Marczyk, A., Konradi, A., Nguyen, M., Haditsch, U., Raha, D., Griffin, C., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau3333 · Cited by 1,966 · cited 1×
“gingivalis infection of mice result in neuronal loss in brain combined with increased Aβ42 and TNFα inflammatory factor (87).”
BackgroundOxidative Stress, Synaptic Dysfunction, and Alzheimer’s Disease
Tönnies, E., & Trushina, E. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161088 · Cited by 1,750
Cysteine cathepsins: From structure, function and regulation to new frontiers
Turk, V., Stoka, V., Vasiljeva, O., Renko, M., Sun, T., Turk, B., & Turk, D. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.10.002 · Cited by 1,377
Lysosomal acidification mechanisms
Mindell, J. A. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142317 · Cited by 1,258
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Cited by
Targeting lysosomes in human disease: from basic research to clinical applications
Cao, M., Luo, X., Wu, K., & He, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00778-y · Cited by 225
“The expression of cathepsins, the important executors of lysosomal degradation, was deregulated in cells of neurodegenerative diseases, and they showed reduced efficiency in degrading misfolded proteins and deregulated expression.(14,175) For example, cathepsin D, the hydrolase responsible for degrading HTT, was ident…”
BackgroundInfluentialLo, C. H., & Zeng, J. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00362-0 · Cited by 117
Gao, L., Wang, J., & Bi, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s549893 · Cited by 52
Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer’s disease pathogenesis
Yuyama, K., Sun, H., Fujii, R., Hemmi, I., Ueda, K., & Igeta, Y. (2024) · Brain · doi:10.1093/brain/awad361 · Cited by 47
Sumsuzzman, D. M., Khan, Z. A., Choi, J., & Hong, Y. (2021) · Aging · doi:10.18632/aging.202894 · Cited by 19
Peroxisomal defects in microglial cells induce a disease-associated microglial signature
Raas, Q., Tawbeh, A., Tahri-Joutey, M., Gondcaille, C., Keime, C., Kaiser, R., Trompier, D., Nasser, B., Leoni, V., Bellanger, E., et al. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1170313 · Cited by 16
“Elevated levels of cathepsin B have been detected in biological fluids of patients with brain diseases (Hook et al., 2020).”
BackgroundWu, Y., Mumford, P., Noy, S., Cleverley, K., Mrzyglod, A., Luo, D., van Dalen, F., Verdoes, M., Fisher, E. M. C., & Wiseman, F. K. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01632-8 · Cited by 16
Rivier, C. A., Diaz-Perez, S., Bories, G., Huo, S., Clocchiatti-Tuozzo, S., de Havenon, A., Debette, S., Sheth, K. N., Sansing, L. H., & Falcone, G. J. (2026) · Stroke · doi:10.1161/strokeaha.126.056508
Metadata
- Authors
- Hook, V., Yoon, M., Mosier, C., Ito, G., Podvin, S., Head, B. P., Rissman, R., O'Donoghue, A. J., & Hook, G.
- Venue
- Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 1868
- Issue
- 8
- Pages
- 140428
- ISSN
- 1570-9639 (ISSN-L)
- OpenAlex
- W3016705584
- Cited by
- 173
- References
- 38
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.